Innovent Biologics Reports the P-III Trial Results of Mazdutide for Treating Type 2 Diabetes
Shots:
- The P-III (DREAMS-2) trial assesses the safety & efficacy of mazdutide (4mg, 6mg) vs dulaglutide (1.5mg) in T2D Chinese patients (n=731) having inadequate glycemic control with metformin alone or its combinations
- The study after 28wks. depicted improved HbA1c level from baseline confirming the superiority of mazdutide. Statistical superiority was seen in HbA1c change & percent change in body wt. from baseline, patient proportion with HbA1c <7.0% & ≥5% wt. loss
- Mazdutide is under review for chronic weight management with the NMPA. The company anticipates P-III (DREAMS-1) study results in mid-2024 with an NDA submission for T2D to the CDE. The DREAMS-1 & DREAMS-2 data analysis will be published in academic congresses or clinical journals
Ref: Innovent | Image: Innovent
Related News:- Innovent Reports the Acceptance of its NDA by the NMPA for Mazdutide to Treat Overweight or Obese Adults
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.